

# NGS-based viral diagnostics, let's confront some challenges


**T. Candresse, A. Marais, C. Faure & S. Theil**

*[thierry.candresse@inra.fr](mailto:thierry.candresse@inra.fr)*

# Why such an impact of NGS ?

## NGS

- Brings a **non-biased** and **potentially complete** vision of the sanitary state of a sample
- Speeds up the time between virus discovery and availability of a **diagnostic test**
- Allows to **improve classical PCR or LAMP assays** through the improvement of primers by integrating more complete information on viral diversity
- But also allows other studies, like virus **population genetics and evolution**, virus **ecology** ...



- **In most situations virus discovery imposes fewer constraints than diagnostics**  
*(if no virus is found, then retest or test another sample...)*
- **But the results of a diagnostic test should be as close as possible to the true infection status of a sample**
- **So a diagnostic test has to be**
  - Sensitive
  - Specific (or broad-spectrum)
  - Accurate (absence of false positives or of false negatives)
  - Repeatable
  - *and also cost- and time-effective*

- **Very few direct comparisons with PCR or ELISA**
- **Sensitivity known to be impacted by**
  - Viral concentration
  - Sequencing depth
  - Bioinformatic pipeline
- **COST proficiency test (siRNAs)**
  - Only **1/3<sup>rd</sup>** of pipelines had 100% sensitivity (*3 with false positives*)
  - ...and only **2/3<sup>rd</sup>** had full repeatability... (2 pseudoreplicates)
- **Sensitivity possibly impacted by**
  - Target nucleic acid population
  - N.A. extraction/purification protocol (cf. host)
  - Mixed infections
- **Overall, testing currently less trivial than some might have hoped**

## Barley samples, dsRNASeq, multiplexed MiSeq 2x250 bp

Two constrained situations depending on the presence or not of the Barley endornavirus (dsRNA virus)

|      | total reads | Viral reads | Endornavirus | BaYMV RNA1 | BaYMV RNA2 | New virus RNA1 | New virus RNA2 |
|------|-------------|-------------|--------------|------------|------------|----------------|----------------|
| # 38 | 350,000     | 53%         | 2000x        | 0.14x      | 2x         | 0.2x           | 3.9x           |
| # 15 | 283,822     | 59%         | na           | 140x       | 2000x      | 1600x          | 1000x          |

- Strong variation in coverage limited ability to assemble the genomes of co-infecting viruses when the Endornavirus was present
- Could limit the ability to detect one of the viruses, in particular if lower enrichment or sequencing depth,
- Overall, **Excellent correlation with PCR detection (95.2%)**, two infection cases with <0.1% of reads but not detected by PCR

- **Specificity: critical for identification**
- **Because NGS diagnostics is sequence-based and unbiased, specificity should not be a concern**
- **But there are situations where data analysis may provide ambiguous results**
  - Novel virus: Blast analysis may not easily separate between presence of a novel agent or of a distant isolate of a known one (in particular if only partial genome coverage)
  - Closely related viruses. Blast and/or mapping analyses may not allow easily to know which virus is present (or both !)
  - In particular, for mapping there is a fine balance between too stringent parameters (may miss a divergent isolate) and too relaxed parameters (give a cross-mapping signal with a closely related virus)

# Determining the infection status

- Italian cherry sample, dsRNA sequencing

|   | Contigs | % of total reads | Blast e-values |
|---|---------|------------------|----------------|
| <i>Little cherry virus 1</i>              | 14      | 28.0%            | 0 to 6e-49     |
| <i>Apple chlorotic leaf spot virus</i>    | 13      | 9.6%             | 0 to 4e-12     |
| <i>Prune dwarf virus</i>                  | 8       | 5.9%             | 0 to 1e-30     |
| <i>Cherry green ring mottle virus</i>     | 2       | 0.5%             | 6e-64 to 3e-27 |
| <i>Peach mosaic virus</i>                 | 2       | 0.2%             | 6e-40 to 3e-30 |
| <i>Cherry necrotic rusty mottle virus</i> | 1       | 0.2%             | 2e-10          |
| <i>Potato virus T</i>                     | 1       | 16.0%            | 7e-68          |
| <i>Mint virus 2</i>                       | 1       | 11.1%            | 8e-86          |
| <i>Banana mild mosaic virus</i>           | 1       | 2.7%             | 4e-11          |
| <i>Scaveola virus A</i>                   | 1       | 0.8%             | 3e-16          |


Which viruses infect the tested cherry tree ??

LChV1, ACLSV, PDV, new *Tepovirus* (*Betaflexiviriae*)


# All mapped reads are not equal....

- **Grapevine sample, RNASeq, mapping analysis**
  - 145 Reads *Grapevine Pinot gris virus* (GPgV)
  - 116 reads *Grapevine fleck virus* (GFkV)

GPgV



GFkV



contamination by a PCR product or cross-mapping with another agent (or cellular sequences)

# Mapping stringency matters...

Grapevine, total RNASeq, mapping of reads against reference database

|       | Reads mapped using various stringencies |     |      |      |
|-------|---|-----|------|------|
|       | 100%                                    | 90% | 80%  | 70%  |
| GfKV  | 0                                       | 5   | 17   | 401  |
| GRVFV | 0                                       | 203 | 4301 | 4774 |

Mapping stringency may ultimately need to be fine tuned for each virus, taking into account its variability and that of related agents

## But

- \* Very difficult and time consuming to use different stringency parameters for each virus >> use compromise
- \* Our knowledge of viral variability is incomplete... (new divergent strains regularly detected...)
- \* In some cases, it may not be possible to select an optimal stringency (interspecific recombinant viruses...)

- **False negatives ? cf sensitivity & specificity**
  - Performance of bioinformatic pipeline
  - **COST proficiency test**: only **2/12** pathogens detected by all pipelines at highest sequencing depth
  - Novel viruses too divergent to recognize by a Blast-based approach ? Additionnally use motive searches (Hmmscan...)
- **False positives ? cf specificity plus other issues**
  - Need for expertise when looking at pipeline results
  - For DNA viruses, integrated or episomal virus ???  
*(in particular for Caulimoviridae members in RNAseq)*
  - Contamination (diagnostic lab or sequencing platform).  
NGS at least as susceptible to contaminations as PCR  
(one or more PCR step(s) in most NGS protocols)

# Example of contamination

Ribo-depleted RNASeq on germinating radish seedling

|                  | Reads/virus/10 <sup>6</sup> reads |                   |       |       |       |
|------------------|-----------------------------------|-------------------|-------|-------|-------|
|                  | New Bunyaviridae                  | New Cryptic virus | RsCV2 | PhMCV | PvEV1 |
| Radish #1        | 25828                             | 59213             | 256   | 1466  | 1515  |
| Radish #2        | 27164                             | 120436            | 1280  | 685   | 1799  |
| PCR on seedlings | -                                 | +                 | +     | -     | -     |

## Novel *Bunyaviridae*

Near complete genome assembled

Origin of contamination ???

Sequencing platform ?

## *Physotegia chlorotic mottle virus*

Complete genome assembled

Origin of contamination ???

Sequencing platform ?

## *Phaseolus endornavirus 1*

Complete genome

Likely lab contamination,  
frequent bean samples

- NGS technologies have already drastically changed virus discovery and etiology
- They have the potential to **drastically change** the field of viral indexing/diagnostics, providing **faster, cheaper and more complete results**, with many applications
  - Certification/quality control
  - Quarantine
- There are pitfalls and challenges, **NGS is more complicated than PCR** and some expertise is needed
- Similar to the situation with PCR in its early years, much work still needed for full adoption in diagnostics
  - **Comparative performance** with existing assays (*sensitivity, repeatability...*)
  - Validated protocols, including **data analysis & detection thresholds** (*Benchmarking, Proficiency tests, Ringtests...*)
  - **Quality management** systems, Standards...

# Many thanks to...

**BFP**

- **Bordeaux team**

A. Marais  
C. Faure  
L. Svanella  
S. Theil



- **All COST DIVAS members and in particular**

S. Massart  
T. Wetzel  
A. Olmos



- Many other colleagues and collaborators with whom I exchanged ideas...



*GRAZIE MILLE !  
THANK YOU !*